- /
- Supported exchanges
- / US
- / VRXAW.US
Veraxa Biotech AG Warrants (VRXAW US) stock market data APIs
Veraxa Biotech AG Warrants Financial Data Overview
VERAXA Biotech AG develops antibody-based therapeutics and antibody-drug conjugates for cancer treatment. The company develops antibody-based therapeutics, including antibody-drug conjugates and bispecific antibody formats, and offers a proprietary technology platform for functional antibody screening and bioconjugation. Its product pipeline includes drug candidates such as ADCs and BITACs, with some in clinical development, and it provides partnership models for collaborative development from target identification to antibody and ADC creation. The company utilizes proprietary payloads and genetic code expansion technology to engineer and manufacture homogeneous, stable bioconjugates with defined drug-to-antibody ratios. It also licenses technology platforms to support the development of new therapeutic strategies. The company serves professional clients in the healthcare sector, including those in drug development, biologicals, diagnostics, instrumentation, and partners with research organizations and business partners in the life sciences industry. The company was founded in 2021 and is based in Heidelberg, Germany.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Veraxa Biotech AG Warrants data using free add-ons & libraries
Get Veraxa Biotech AG Warrants Fundamental Data
Veraxa Biotech AG Warrants Fundamental data includes:
- Net Revenue: 23 426
- EBITDA: -64 244 176
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
Get Veraxa Biotech AG Warrants Earnings data
Corporate Events Calendar & News package for
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Veraxa Biotech AG Warrants News
New
The Cancer Therapy Strategy VERAXA Is Betting the Company On
By Karen Roman VERAXA Biotech AG (Nasdaq: VRXA) said it expects BiTAC molecules to be the company's main value drivers and to dominate its pipeline development in the upcoming years, hence receiving ...
VERAXA Biotech Stock in Focus as Lead Cancer Program Reaches Development Milestone
By Karen Roman VERAXA Biotech AG (Nasdaq: VRXA) said it started cell line development for its lead BiTAC T-cell engager program, collaborating with ATUM to apply proprietary technology for stable clo...
Why VERAXA Biotech (VRXA) Shareholders Should Pay Serious Attention to Antibody Therapeutics Sector Deals
LOS ANGELES, CA - July 1, 2026 (NEWMEDIAWIRE) - Biotechnology investors often focus on clinical milestones, regulatory approvals, and commercial launches. Yet in antibody therapeutics, some of the lar...
VERAXA Unveils Cancer Therapy Platform, Sparks Partnering Talks at BIO 2026
By Karen Roman Veraxa Biotech AG (Nasdaq: VRXA) reported in vitro proof-of-concept data validating its BiTAC-ADC platform for cancer therapies, with selective tumor cell killing while sparing healthy...
Corporate Events Calendar & News package for
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.